Top

Published in:

09-08-2022 | Breast Cancer | Original Article

Hypofractionated radiotherapy after breast-conserving surgery: Clinical and dosimetric factors predictive of acute skin toxicity

Authors: Dr. Raouia Ben Amor, Meriem Bohli, Zeineb Naimi, Dorra Aissaoui, Nesrine Mejri, Jamel Yahyaoui, Awatef Hamdoun, Lotfi Kochbati

Published in: Strahlentherapie und Onkologie | Issue 1/2023

Abstract

Purpose

The purpose of this study was to evaluate acute skin toxicity in early breast cancer patients treated with hypofractionated radiotherapy (HFRT) after breast-conserving surgery and to identify factors predictive for grade ≥ 2 acute skin toxicity.

Materials and methods

A monocentric retrospective study was carried out using cases treated between December 2017 and November 2020. We analyzed data from 202 patients with early breast cancer treated with 3D hypofractionated RT (40.05 Gy in 15 fractions) to the whole breast with or without regional lymph nodes, followed by 13.35 Gy in 5 fractions to the tumor bed. Acute skin toxicity was monitored during RT according to CTCAE (common toxicity criteria for adverse events) scale. Univariate and multivariate analyses were performed to assess predictive factors of acute skin toxicity.

Results

Overall, there was no erythema in 9%, grade 1 erythema in 64.5%, grade 2 in 24%, and grade 3 in 2.5%. No grade 4 erythema was seen. Median delay between RT initiating and maximum skin reaction was 22 days (range 4–44 days). No patient interrupted treatment. In univariate analysis, the rate of acute skin toxicity grade 2--–3 (G2-3) was significantly higher for patients with larger tumor size (p = 0.02), body mass index > 27 (p = 0.04), and time between chemotherapy (CT) and RT less than 20 days (p = 0.01). Dosimetric risk factors for acute skin toxicity G2‑3 were breast volume > 800 cc (p = 0.000), boost volume > 18 cc (p = 0.002), V105% > 40 cc (p = 0.03), and Dmax > 56 Gy (p = 0.007). CT, trastuzumab, regional lymph node radiation, and age were not correlated with increased skin toxicity. In multivariate analysis, acute skin toxicity correlated with T stage (p = 0.032), breast volume > 800 cc (p = 0.012), boost volume > 18 cc (p = 0.04), and Dmax > 56 Gy (p = 0.035).

Conclusion

Our results confirm that whole breast with or without lymph nodes hypofractionated RT is safe and well tolerated. The factors strongly associated with a decreased risk of G2‑3 skin toxicity are T1, breast volume < 800 c, boost volume < 18 cc, and Dmax < 56 Gy. Long-term follow-up is needed to evaluate late toxicity.

EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 383(9935):2127–2135CrossRef

START Trialists’ Group, Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ et al (2008) The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet 371(9618):1098–1107CrossRef

Whelan TJ, Kim D‑H, Sussman J (2008) Clinical experience using hypofractionated radiation schedules in breast cancer. Semin Radiat Oncol 18(4):257–264CrossRef

Shaitelman SF, Schlembach PJ, Arzu I, et al (2015) Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: A randomized clinical trial. JAMA Oncol 1(7):931–941. https://doi.org/10.1001/jamaoncol.2015.2666CrossRef

Murray Brunt A, Haviland JS, Wheatley DA, et al (2020) Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet 395(10237):1613–1626. https://doi.org/10.1016/S0140-6736(20)30932-6CrossRef

CTEP Common terminology criteria for adverse events (CTCAE) | protocol development. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed 12.2021

Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Biete Sola A et al (2015) ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiother Oncol 114(1):3–10CrossRef

Sanz J, Rodríguez N, Foro P, et al (2017) Hypofractionated boost after whole breast irradiation in breast carcinoma: chronic toxicity results and cosmesis. Clin Transl Oncol 19(4):464–469. https://doi.org/10.1007/s12094-016-1548-3CrossRef

Tortorelli G, Di Murro L, Barbarino R, Cicchetti S, di Cristino D, Falco MD et al (2013) Standard or hypofractionated radiotherapy in the postoperative treatment of breast cancer: a retrospective analysis of acute skin toxicity and dose inhomogeneities. Bmc Cancer 13(1):230. https://doi.org/10.1186/1471-2407-13-230CrossRef

10.

Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A et al (2016) Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3‑week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol 120(1):114–118CrossRef

11.

Hickey BE, James ML, Lehman M, Hider PN, Jeffery M, Francis DP et al (2016) Fraction size in radiation therapy for breast conservation in early breast cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003860.pub4CrossRef

12.

Nozaki M, Kagami Y, Shibata T, Nakamura K, Ito Y, Nishimura Y et al (2019) A primary analysis of a multicenter, prospective, single-arm, confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906. Jpn J Clin Oncol 49(1):57–62. https://doi.org/10.1093/jjco/hyy160CrossRef

13.

Yarnold J, Ashton A, Bliss J, Homewood J, Harper C, Hanson J et al (2005) Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial. Radiother Oncol 75(1):9–17CrossRef

14.

Holloway CL, Panet-Raymond V, Olivotto I (2010) Hypofractionation should be the new ‘standard’ for radiation therapy after breast conserving surgery. Breast 19(3):163–167CrossRef

15.

Dorn PL, Corbin KS, Al-Hallaq H, Hasan Y, Chmura SJ (2012) Feasibility and acute toxicity of Hypofractionated radiation in large-breasted patients. Int J Radiat Oncol Biol Phys 83(1):79–83CrossRef

16.

Ciammella P, Podgornii A, Galeandro M, Micera R, Ramundo D, Palmieri T et al (2014) Toxicity and cosmetic outcome of hypofractionated whole-breast radiotherapy: predictive clinical and dosimetric factors. Radiat Oncol 9(1):97. https://doi.org/10.1186/1748-717X-9-97CrossRef

17.

Harsolia A, Kestin L, Grills I, Wallace M, Jolly S, Jones C et al (2007) Intensity-modulated radiotherapy results in significant decrease in clinical toxicities compared with conventional wedge-based breast radiotherapy. Int J Radiat Oncol Biol Phys 68(5):1375–1380CrossRef

18.

Hijal T, Al Hamad AA, Niazi T, Sultanem K, Bahoric B, Vuong T et al (2010) Hypofractionated radiotherapy and adjuvant chemotherapy do not increase radiation-induced dermatitis in breast cancer patients. Curr Oncol 17(5):22–27CrossRef

19.

Kouloulias V, Zygogianni A, Kypraiou E, Georgakopoulos J, Thrapsanioti Z, Beli I et al (2014) Adjuvant chemotherapy and acute toxicity in hypofractionated radiotherapy for early breast cancer. WJCC 2(11):705–710CrossRef

20.

Zygogianni A, Kouloulias V, Antypas C, Armpilia C, Kyrgias G, Kouvaris J (2014) The impact of intermediate time between chemotherapy and hypofractionated radiotherapy to the radiation induced skin toxicity for breast adjuvant treatment. Breast J 20(1):74–78. https://doi.org/10.1111/tbj.12206CrossRef

21.

De Langhe S, Mulliez T, Veldeman L, Remouchamps V, van Greveling A, Gilsoul M et al (2014) Factors modifying the risk for developing acute skin toxicity after whole-breast intensity modulated radiotherapy. Bmc Cancer 14(1):711. https://doi.org/10.1186/1471-2407-14-711CrossRef

22.

Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K et al (2010) Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol 11(3):258–265CrossRef

23.

Keenan LG, Lavan N, Dunne M, McArdle O (2019) Modifiable risk factors for acute skin toxicity in adjuvant breast radiotherapy: dosimetric analysis and review of the literature. Med Dosim 44(1):51–55CrossRef

24.

Taher AN, El-Baradie MM, Essa H, Zaki O, Ezzat S (2004) Hypofractionation versus conventional fractionation radiotherapy after conservative treatment of breast cancer: early skin reactions and cosmetic results. J Egypt Natl Canc Inst 16(3):178–187

25.

De Santis MC, Bonfantini F, Di Salvo F, Dispinzieri M, Mantero E, Soncini F et al (2016) Factors influencing acute and late toxicity in the era of adjuvant hypofractionated breast radiotherapy. Breast 29:90–95CrossRef

Title: Hypofractionated radiotherapy after breast-conserving surgery: Clinical and dosimetric factors predictive of acute skin toxicity
Authors: Dr. Raouia Ben Amor
Meriem Bohli
Zeineb Naimi
Dorra Aissaoui
Nesrine Mejri
Jamel Yahyaoui
Awatef Hamdoun
Lotfi Kochbati
Publication date: 09-08-2022
Publisher: Springer Berlin Heidelberg
Keywords: Breast Cancer
Breast Cancer
Radiotherapy
Erythema
Trastuzumab
Cytostatic Therapy
Published in: Strahlentherapie und Onkologie / Issue 1/2023
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-022-01985-4

At a glance: The STEP trials

Springer Medicine

Hypofractionated radiotherapy after breast-conserving surgery: Clinical and dosimetric factors predictive of acute skin toxicity

Abstract

Purpose

Materials and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Fertilitätserhaltung bei Brustkrebs – ein Risiko?

Prerequisites for the clinical implementation of a markerless SGRT-only workflow for the treatment of breast cancer patients

Surface-guided DIBH radiotherapy for left breast cancer: impact of different thresholds on intrafractional motion monitoring and DIBH stability

Meningeomrisiko nach der Behandlung von Krebs im Kindesalter. Eine gepoolte Datenanalyse

Most recent update of preclinical and clinical data on radioresistance and radiosensitivity of high-grade gliomas—a radiation oncologist’s perspective

Combined-modality treatment for locally advanced cervical cancer in a woman with Bloom-like syndrome: A case report and review of the literature